Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Rasburicase 0,20mg/Kg/Day once a day 3-7 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rasburicase | Drug | Rasburicase 0,20mg/Kg/Day once a day 3-7 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia) | 24-48 hours after last dose of rasburicase | |
| Percentage of patients with uric acid greater-than-normal laboratory levels (hyperuricemia) | 28 (+- 3) days after the last dose of rasburicase | |
| Adverse events occurrence | During the study |
Not provided
Not provided
List of inclusion Criteria:
List of exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jaderson Lima | Sanofi-aventis administrative office Brazil | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sanofi-aventis administrative office | São Paulo | Brazil |
Not provided
| ID | Term |
|---|---|
| D033461 | Hyperuricemia |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C469709 | rasburicase |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided